BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1795 related articles for article (PubMed ID: 29727246)

  • 1. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
    Lin C; Zhang J
    Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering T cells for adoptive therapy: outsmarting the tumor.
    Kunert A; Debets R
    Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
    Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
    Front Immunol; 2021; 12():738456. PubMed ID: 34721401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Next generation engineered T cells for cell therapy: from lymphoma to solid tumors].
    Catros V
    Med Sci (Paris); 2019 Apr; 35(4):316-326. PubMed ID: 31038109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 18. Engineering chimeric antigen receptor-T cells for cancer treatment.
    Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
    Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.
    Morgan MA; Schambach A
    Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 90.